Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G. | Psychotherapy and psychosomatics | December 2020
The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats
Brandt, S. D., Walters, H. M., Partilla, J. S., Blough, B. E., Kavanagh, P. V., & Baumann, M. H. | Psychopharmacology | 01 September 2020
Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans
Davis, A. K., Averill, L. A., Sepeda, N. D., Barsuglia, J. P., & Amoroso, T. | Chronic Stress | 8 July 2020
In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor
Pottie, E., Cannaert, A., & Stove, C. P | Archives of Toxicology | 5 July 2020
Spotlight commentary: REBUS and the anarchic brain
Carhart-Harris, R. L., & Friston, K. J. | Pharmacological reviews | 12 June 2020
Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland
Kangaslampi, S., Hausen, A., & Rauteenmaa, T. | Journal of Psychoactive Drugs | 8 June 2020
Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan
Carbonaro, T. M., Johnson, M. W., & Griffiths, R. R | Psychopharmacology | 5 June 2020
Can Psychedelics Alleviate Symptoms of Cluster Headache and Accompanying Mental Health Problems? A Case Report Involving Hawaiian Baby Woodrose
Johnson, S., & Black, Q. C. | Journal of Psychoactive Drugs | 7 May 2020
Long-term effects of psychedelic drugs: A systematic review
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. | Neuroscience & Biobehavioral Reviews | 15 March 2020
Reviewing the Potential of Psychedelics for the Treatment of PTSD.
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. | International Journal of Neuropsychopharmacology | 14 March 2020
The Psychedelic Renaissance and Its Forensic Implications
Holoyda, B. | The journal of the American Academy of Psychiatry and the Law | 09 Mar 2020
Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects.
Lancelotta, R. L., & Davis, A. K. | Journal of Psychoactive Drugs | 09 Mar 2020
In vivo effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in rodents: Drug discrimination and thermoregulation.
Berquist, M. D., Leth-Petersen, S., Kristensen, J. L., & Fantegrossi, W. E. | Drug and Alcohol Dependence | 13 January 2020
A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamine
Palamar, J. J., & Acosta, P. | Clinical and Experimental | 07 January 2020
Esketamine is approved in Europe for treating resistant major depressive disorder
Mahase, E. | BMJ | 20 December 2019
Neurochemical and Behavioral Profiling in Male and Female Rats of the Psychedelic Agent 25I-NBOMe
Miliano, C., Marti, M., Pintori, N., Castelli, M. P., Tirri, M., Arfè, R., & De Luca, M. A. | Frontiers in Pharmacology | 12 December 2019
4-MeO-PCP and 3-MeO-PCMo, new dissociative drugs, produce rewarding and reinforcing effects through activation of mesolimbic dopamine pathway and alteration of accumbal CREB, deltaFosB, and BDNF levels
Abiero, A., Botanas, C. J., Custodio, R. J., Sayson, L. V., Kim, M., Lee, H. J. & Cheong, J. H. | Psychopharmacology | 11 December 2019
Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment
Uthaug, M. V., Lancelotta, R., Szabo, A., Davis, A. K., Riba, J., & Ramaekers, J. G. | Psychopharmacology | 10 December 2019
Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders
Sartori, S. B., & Singewald, N. | Pharmacology & therapeutics | 27 August 2019
Effects of the synthetic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) on ethanol consumption and place conditioning in male mice.
Oppong-Damoah, A., Curry, K. E., Blough, B. E., Rice, K. C., & Murnane, K. S. | Psychopharmacology | 15 July 2019
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.
Carhart-Harris, R. L., & Friston, K. J. | Pharmacological reviews | 1 July 2019
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics
Carhart-Harris, R. L., & Friston, K. J. | Pharmacological reviews | 20 June 2019
Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD).
Brandt, S. D., Kavanagh, P. V., Westphal, F., Stratford, A., Elliott, S. P., Dowling, G., ... & Halberstadt, A. L. | Drug testing and analysis | 18 June 2018
Motives and side-effects of microdosing with psychedelics among users
Hutten, N. R., Mason, N. L., Dolder, P. C., & Kuypers, K. P. | International Journal of Neuropsychopharmacology | 31 May 2019
Palliative Nursing and Sacred Medicine: A Holistic Stance on Entheogens, Healing, and Spiritual Care.
Rosa, W. E., Hope, S., & Matzo, M. | Journal of Holistic Nursing | 18 April 2018